BR112013005300A2 - composições que compreendem extratos ácidos da goma mástique - Google Patents

composições que compreendem extratos ácidos da goma mástique

Info

Publication number
BR112013005300A2
BR112013005300A2 BR112013005300A BR112013005300A BR112013005300A2 BR 112013005300 A2 BR112013005300 A2 BR 112013005300A2 BR 112013005300 A BR112013005300 A BR 112013005300A BR 112013005300 A BR112013005300 A BR 112013005300A BR 112013005300 A2 BR112013005300 A2 BR 112013005300A2
Authority
BR
Brazil
Prior art keywords
compositions
mastic gum
acid extracts
mastic
gum
Prior art date
Application number
BR112013005300A
Other languages
English (en)
Other versions
BR112013005300B1 (pt
Inventor
Andre C B Lucassen
Zadik Hazan
Original Assignee
Regenera Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenera Pharma Ltd filed Critical Regenera Pharma Ltd
Priority to BR122019022461-7A priority Critical patent/BR122019022461B1/pt
Publication of BR112013005300A2 publication Critical patent/BR112013005300A2/pt
Publication of BR112013005300B1 publication Critical patent/BR112013005300B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)

Abstract

composições que compreendem extratos ácidos da goma mástique. a presente invenção refere-se a composições e formulações que compreendem uma fração ácida isolada da goma mástique e seus usos no tratamento de funções neurológicas comprometidas, bem como na reparação de tecidos e feridas.
BR112013005300-3A 2010-09-07 2011-09-07 Composição que compreende extratos ácidos de goma mástique BR112013005300B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019022461-7A BR122019022461B1 (pt) 2010-09-07 2011-09-07 Processo para preparar uma fração ácida isolada de goma mástique

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38033910P 2010-09-07 2010-09-07
US61/380,339 2010-09-07
PCT/IL2011/000724 WO2012032523A2 (en) 2010-09-07 2011-09-07 Compositions comprising acidic extracts of mastic gum

Publications (2)

Publication Number Publication Date
BR112013005300A2 true BR112013005300A2 (pt) 2016-08-16
BR112013005300B1 BR112013005300B1 (pt) 2021-11-09

Family

ID=45811024

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019022461-7A BR122019022461B1 (pt) 2010-09-07 2011-09-07 Processo para preparar uma fração ácida isolada de goma mástique
BR112013005300-3A BR112013005300B1 (pt) 2010-09-07 2011-09-07 Composição que compreende extratos ácidos de goma mástique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019022461-7A BR122019022461B1 (pt) 2010-09-07 2011-09-07 Processo para preparar uma fração ácida isolada de goma mástique

Country Status (13)

Country Link
US (4) US9271949B2 (pt)
EP (2) EP2613777B1 (pt)
JP (3) JP5876052B2 (pt)
KR (2) KR101910781B1 (pt)
CN (2) CN103167871B (pt)
AU (1) AU2011300359B2 (pt)
BR (2) BR122019022461B1 (pt)
CA (1) CA2810472A1 (pt)
DK (1) DK2613777T3 (pt)
ES (1) ES2732559T3 (pt)
IL (2) IL225004B (pt)
PL (1) PL2613777T3 (pt)
WO (1) WO2012032523A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810472A1 (en) 2010-09-07 2012-03-15 Regenera Pharma Ltd. Compositions comprising acidic extracts of mastic gum
IL237621A0 (en) * 2015-03-08 2015-06-30 Regenera Pharma Ltd Use of isolated fractions of the gum goddess to treat optic neuropathy
IL258279B (en) 2015-09-24 2022-09-01 Regenera Pharma Ltd Preparations containing triterpenoids
AU2016327286A1 (en) 2015-09-24 2018-04-12 Regenera Pharma Ltd. Compositions comprising triterpenoids
CN106178068B (zh) * 2016-08-18 2017-09-19 广州华弘生物科技有限公司 一种促进伤口愈合的贴膜及缝合器
AU2017322654A1 (en) 2016-09-08 2019-04-04 Regenera Pharma Ltd. Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy
EA201990560A1 (ru) 2016-09-08 2019-09-30 Регенера Фарма Лтд. Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
FR3057467B1 (fr) * 2016-10-17 2018-12-07 IFP Energies Nouvelles Procede de purification d'une solution aqueuse comprenant du diethylacetal
WO2019170239A1 (en) * 2018-03-08 2019-09-12 Phytoitalia Srl Terpene enriched fractions free from polyterpenes extracted from chios mastic gum and cosmetic, nutraceutical, medical devices and pharmaceutical compositions containing them
IL262050B (en) * 2018-10-02 2020-04-30 Unv Medicine Ltd Compositions comprising cbd for treating hemorrhoids
WO2020121218A2 (en) * 2018-12-11 2020-06-18 Giuseppe Cannazza Extraction method and composition obtained therefrom
CN109363975A (zh) * 2018-12-17 2019-02-22 广州诗美化妆品有限公司 一种化妆品用乳香提取物的制备方法与应用
KR102603568B1 (ko) * 2023-03-30 2023-11-20 주식회사 프롬바이오 수용화 매스틱 검을 이용한 피부장벽 기능 개선용 조성물

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
US5714007A (en) 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
GR950100243A (el) 1995-06-28 1997-02-28 �. �����- �. ����� �.�.�. Χρησιμοποιηση της φυσικης μαστιχας χιου η του εξαγομενου εξ'αυτης φυσικου μαστιχελαιου η συνθετικων παραγωγων του για την παρασεκυη οδοντοκρεμας, οδοντικου διαλυματος, αποσμητικου στοματος, αντιηλιακων, προιοντων μαλλιων, καθως και καλλυντικων προιοντων.
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
AU2107199A (en) 1998-01-08 1999-07-26 Regents Of The University Of California, The Kinesin motor modulators derived from the marine sponge (adocia)
GR1003541B (el) 1999-05-11 2001-03-07 Αντιμικροβιακη και αντιμυκητιακη δραση του εξαγομενου απο τα κλαδια, φυλλα και καρπο της μαστιχας χιου -pistacia lentiscus var chia-, μαστιχελαιου, για χρηση σε καλλυντικες, φαρμακευτικες και παραφαρμακευτικεσς εφαρμογες καθως και στην παραγωγη οδοντοτσι
GR1003550B (el) 1999-09-22 2001-03-13 Σταθερο παρασκευασμα ισοεξυλοναφθαζαρινων με πεντα- και τετρα-κυκλικα τριτερπενια, συστατικα φυτικων ελαιορητινων και κομμεων
US6623728B2 (en) 2000-06-30 2003-09-23 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Cosmetic skin care compositions and containing gum mastic
GR1003868B (el) 2001-02-06 2002-04-19 Lavipharm S.A. Αξιολογηση των επουλωτικων, αντιοξειδωτικων και κυτταροστατικων ιδιοτητων της μαστιχας και των συστατικων της, και οι εφαρμογες τους
IL156976A0 (en) 2001-02-13 2004-02-08 Yissum Res Dev Co Carotenoid-loaded liposomes
US6534548B1 (en) 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
EP1501527B1 (en) 2002-05-01 2009-09-02 Lavipharm S.A. Use of mastic and its essential oils for the control of microbial infections
US7364607B2 (en) 2002-05-20 2008-04-29 Toyo Boseki Kabushiki Kaisha Wrought fiber sheet and filter unit
JP2004083443A (ja) 2002-08-23 2004-03-18 Hideji Watanabe マスティックを用いた歯周病予防・治療用組成物及び歯周病予防・治療方法
US20050074509A1 (en) 2003-10-02 2005-04-07 Data Medica Padova S.P.A. Cancer treatment using natural plant products or essential oils extracted from some pistacia species or components
FR2867980B1 (fr) 2004-03-23 2006-07-14 Pierre Fabre Medicament Sa Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta
EP1732915B1 (en) 2004-03-29 2016-01-06 University Of Iowa Research Foundation Schweinfurthin analogues
WO2005112967A2 (en) 2004-05-19 2005-12-01 Balfour Marketing Corp. Anticancer activity of chios mastic gum
JP2008505685A (ja) 2004-07-06 2008-02-28 トランスファーマ メディカル リミテッド 経皮免疫処置用送達システム
US7268124B2 (en) 2004-08-25 2007-09-11 University Of Iowa Research Foundation Geranylgeranyl pyrophosphate synthase inhibitors
JP2007135493A (ja) * 2005-11-18 2007-06-07 Health & Health Kk 健康食品
US20070249543A1 (en) * 2006-04-19 2007-10-25 Filiberto Zadini Dissolution of arterial cholesterol plaques by phytochemical emulsifiers
US20080139520A1 (en) 2006-08-22 2008-06-12 Jain Mahendra K Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
KR20100031069A (ko) 2008-09-11 2010-03-19 주식회사 엠디코드 매스틱 추출물 및 그 추출방법
CA2754564C (en) 2009-03-04 2017-09-12 Regenera Pharma Ltd. Therapeutic uses of mastic gum fractions
CN102413834B (zh) * 2009-03-04 2016-11-09 瑞吉纳拉制药公司 聚合月桂烯的组合物
CA2810472A1 (en) * 2010-09-07 2012-03-15 Regenera Pharma Ltd. Compositions comprising acidic extracts of mastic gum
US20150246087A1 (en) * 2012-06-11 2015-09-03 Regenera Pharma Ltd. Extracts and therapeutic uses thereof

Also Published As

Publication number Publication date
WO2012032523A3 (en) 2012-07-05
BR112013005300B1 (pt) 2021-11-09
KR101875984B1 (ko) 2018-07-06
WO2012032523A2 (en) 2012-03-15
US10159680B2 (en) 2018-12-25
EP2613777A4 (en) 2015-08-12
EP2613777B1 (en) 2019-05-01
KR101910781B1 (ko) 2018-10-22
CN103167871A (zh) 2013-06-19
EP2613777A2 (en) 2013-07-17
AU2011300359B2 (en) 2014-03-06
IL256881A (en) 2018-03-29
US20160199389A1 (en) 2016-07-14
JP2016121166A (ja) 2016-07-07
BR122019022461B1 (pt) 2022-03-15
JP6314265B2 (ja) 2018-04-18
US20170368076A1 (en) 2017-12-28
ES2732559T3 (es) 2019-11-25
JP6097420B2 (ja) 2017-03-15
CA2810472A1 (en) 2012-03-15
JP2017114893A (ja) 2017-06-29
JP2013536877A (ja) 2013-09-26
PL2613777T3 (pl) 2019-10-31
US9271949B2 (en) 2016-03-01
CN103167871B (zh) 2017-06-09
JP5876052B2 (ja) 2016-03-02
US9770456B2 (en) 2017-09-26
WO2012032523A9 (en) 2012-05-03
KR20180080345A (ko) 2018-07-11
EP3581177A2 (en) 2019-12-18
DK2613777T3 (da) 2019-07-01
CN106924266A (zh) 2017-07-07
US10561670B2 (en) 2020-02-18
US20190076444A1 (en) 2019-03-14
US20130172416A1 (en) 2013-07-04
IL225004B (en) 2018-01-31
EP3581177A3 (en) 2020-02-26
KR20140037006A (ko) 2014-03-26
AU2011300359A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
BR112013005300A2 (pt) composições que compreendem extratos ácidos da goma mástique
BR112013000537A2 (pt) composição aquosa contendo bromexina
BRPI0802241A2 (pt) células-tronco mesenquimais e seus usos
GT201200056A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112013013167A8 (pt) inibidores de bromodomínio e usos dos mesmos
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CO6571913A2 (es) Derivados de fumarato de ácido graso y sus usos
BR112012033755A2 (pt) composições e métodos antissépticos estáveis
BR112012004698A2 (pt) métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada.
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
BR112016002199A2 (pt) Proteína anti-garp e usos da mesma
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
CO6551677A2 (es) Composiciones orales que contiene extractos de zingiber officinale y métodos relacionados
CO6511249A2 (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
BRPI1013223A2 (pt) usos terapêuticos de frações de goma de mástique
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
BR112012032882A2 (pt) liberação aumentada de ingredientes lopofílicos de goma de mascar com hidrocoloides
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
PH12015500809A1 (en) Chewing gums
BR112015026388A2 (pt) métodos e composições para cicatrização de feridas
BR112015011759A2 (pt) composição simbiótica e uso da mesma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.